S&P 500   4,288.67 (+0.01%)
DOW   33,447.31 (-0.18%)
QQQ   357.55 (-0.20%)
AAPL   171.12 (-0.05%)
MSFT   315.68 (-0.02%)
META   300.70 (+0.16%)
GOOGL   130.31 (-0.42%)
AMZN   126.90 (-0.17%)
TSLA   240.58 (-3.85%)
NVDA   438.16 (+0.73%)
NIO   8.92 (-1.33%)
BABA   86.75 (+0.01%)
AMD   102.65 (-0.17%)
T   15.01 (-0.07%)
F   12.34 (-0.64%)
MU   68.03 (+0.00%)
CGC   0.78 (-0.97%)
GE   110.00 (-0.50%)
DIS   80.82 (-0.28%)
AMC   8.05 (+0.75%)
PFE   33.13 (-0.12%)
PYPL   58.65 (+0.33%)
NFLX   377.00 (-0.16%)
S&P 500   4,288.67 (+0.01%)
DOW   33,447.31 (-0.18%)
QQQ   357.55 (-0.20%)
AAPL   171.12 (-0.05%)
MSFT   315.68 (-0.02%)
META   300.70 (+0.16%)
GOOGL   130.31 (-0.42%)
AMZN   126.90 (-0.17%)
TSLA   240.58 (-3.85%)
NVDA   438.16 (+0.73%)
NIO   8.92 (-1.33%)
BABA   86.75 (+0.01%)
AMD   102.65 (-0.17%)
T   15.01 (-0.07%)
F   12.34 (-0.64%)
MU   68.03 (+0.00%)
CGC   0.78 (-0.97%)
GE   110.00 (-0.50%)
DIS   80.82 (-0.28%)
AMC   8.05 (+0.75%)
PFE   33.13 (-0.12%)
PYPL   58.65 (+0.33%)
NFLX   377.00 (-0.16%)
S&P 500   4,288.67 (+0.01%)
DOW   33,447.31 (-0.18%)
QQQ   357.55 (-0.20%)
AAPL   171.12 (-0.05%)
MSFT   315.68 (-0.02%)
META   300.70 (+0.16%)
GOOGL   130.31 (-0.42%)
AMZN   126.90 (-0.17%)
TSLA   240.58 (-3.85%)
NVDA   438.16 (+0.73%)
NIO   8.92 (-1.33%)
BABA   86.75 (+0.01%)
AMD   102.65 (-0.17%)
T   15.01 (-0.07%)
F   12.34 (-0.64%)
MU   68.03 (+0.00%)
CGC   0.78 (-0.97%)
GE   110.00 (-0.50%)
DIS   80.82 (-0.28%)
AMC   8.05 (+0.75%)
PFE   33.13 (-0.12%)
PYPL   58.65 (+0.33%)
NFLX   377.00 (-0.16%)
S&P 500   4,288.67 (+0.01%)
DOW   33,447.31 (-0.18%)
QQQ   357.55 (-0.20%)
AAPL   171.12 (-0.05%)
MSFT   315.68 (-0.02%)
META   300.70 (+0.16%)
GOOGL   130.31 (-0.42%)
AMZN   126.90 (-0.17%)
TSLA   240.58 (-3.85%)
NVDA   438.16 (+0.73%)
NIO   8.92 (-1.33%)
BABA   86.75 (+0.01%)
AMD   102.65 (-0.17%)
T   15.01 (-0.07%)
F   12.34 (-0.64%)
MU   68.03 (+0.00%)
CGC   0.78 (-0.97%)
GE   110.00 (-0.50%)
DIS   80.82 (-0.28%)
AMC   8.05 (+0.75%)
PFE   33.13 (-0.12%)
PYPL   58.65 (+0.33%)
NFLX   377.00 (-0.16%)
NASDAQ:SVRA

Savara (SVRA) Stock Forecast, Price & News

$3.78
0.00 (0.00%)
(As of 09/29/2023 06:55 PM ET)
Compare
Today's Range
$3.66
$3.80
50-Day Range
$3.25
$3.88
52-Week Range
$1.08
$4.21
Volume
328,400 shs
Average Volume
423,699 shs
Market Capitalization
$510.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Savara MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.3% Upside
$5.00 Price Target
Short Interest
Bearish
3.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.00mentions of Savara in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$999,999 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

491st out of 969 stocks

Pharmaceutical Preparations Industry

229th out of 454 stocks


SVRA stock logo

About Savara (NASDAQ:SVRA) Stock

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

SVRA Price History

SVRA Stock News Headlines

Molgramostim: Savara's Single Shot At Success
Savara Inc.'s (NASDAQ:SVRA) Path To Profitability
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
10% Owner of Savara Makes $999K Buy
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Savara Recent Insider Activity
999K Reasons To Be Bullish On Savara Stock
Savara: A Speculative Play
Savara Prices Share Offering at $3 a Share
Savara joins Russell 3000
Savara (SVRA) Gets a Buy from H.C. Wainwright
See More Headlines
Receive SVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

SVRA Company Calendar

Last Earnings
8/10/2023
Today
10/02/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SVRA
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+32.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-38,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$260,000.00
Book Value
$0.95 per share

Miscellaneous

Free Float
128,982,000
Market Cap
$510.94 million
Optionable
Optionable
Beta
0.87
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Robert N. Neville (Age 51)
    Chairman of the Board, Chief Executive Officer
  • Taneli Jouhikainen (Age 51)
    President, Chief Operating Officer
  • David L. Lowrance (Age 50)
    Chief Financial Officer
  • Nevan C. Elam (Age 49)
    Independent Director
  • Richard J. Hawkins (Age 68)
    Independent Director
  • Joseph S. McCracken Ph.D. (Age 64)
    Independent Director
  • Matthew Pauls J.D.Matthew Pauls J.D. (Age 46)
    Independent Director
  • Yuri Pikover (Age 56)
    Independent Director













SVRA Stock - Frequently Asked Questions

Should I buy or sell Savara stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SVRA shares.
View SVRA analyst ratings
or view top-rated stocks.

What is Savara's stock price forecast for 2023?

2 brokers have issued twelve-month target prices for Savara's shares. Their SVRA share price forecasts range from $4.00 to $6.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 32.3% from the stock's current price.
View analysts price targets for SVRA
or view top-rated stocks among Wall Street analysts.

How have SVRA shares performed in 2023?

Savara's stock was trading at $1.55 at the beginning of 2023. Since then, SVRA shares have increased by 143.9% and is now trading at $3.78.
View the best growth stocks for 2023 here
.

Are investors shorting Savara?

Savara saw a increase in short interest in September. As of September 15th, there was short interest totaling 2,950,000 shares, an increase of 30.5% from the August 31st total of 2,260,000 shares. Based on an average daily volume of 533,000 shares, the short-interest ratio is presently 5.5 days. Currently, 3.5% of the shares of the stock are sold short.
View Savara's Short Interest
.

When is Savara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SVRA earnings forecast
.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01.

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How do I buy shares of Savara?

Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $3.78.

How much money does Savara make?

Savara (NASDAQ:SVRA) has a market capitalization of $510.94 million and generates $260,000.00 in revenue each year. The company earns $-38,150,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The official website for the company is www.savarapharma.com. The company can be reached via phone at 512-614-1848, via email at ir@savarapharma.com, or via fax at 858-552-0876.

This page (NASDAQ:SVRA) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -